Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

Phase 2 Completed 102 enrolled Jiangsu Alphamab Biopharmaceuticals Co., Ltd Peking University · collab

NaSequentialOpen-labelTreatment

Summary

This is an open-label, phase II，multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.

Timeline

Start: 2020-12-07
Primary completion: 2022-01-12
Completion: 2023-05-22

Publications

Liao JY, Wang J, Li H, Liu Z, Tian Z, Lv X, Peng J, Song C, Liu J. Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer. J Immunother Cancer. 2025 Oct 5;13(10):e012629. doi: 10.1136/jitc-2025-012629.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ERFONRILIMAB	Monoclonal antibody	5 mg/kg	—
Subject	KN026	Monoclonal antibody	30 mg/kg	—

Indications

No indication recorded.